Molecular Biomedical Research


We are a group of biology and pharmacy researchers who have common interests in membrane biology & cell signalling (protein-, lipid-, receptor- and transport-mediated processes in health and disease) and technology development. We focus on understanding the molecular basis of signalling and its physiological relevance by studying receptors (e.g. family B GPCRs), channels (e.g. aquaporins and ABC transporters), diseases (e.g. Alzheimer’s disease and epilepsy) and cellular processes (e.g. vesicle trafficking). We do this by using computational (molecular modelling), molecular (structure-function, protein-protein interactions, protein-lipid interactions, recombinant protein production), cellular (phenotypes), whole organism (phenotypes) and analytical (mass spectrometry) science. Our work has relevance to drug discovery (drug delivery with a focus on liposome technology; bioprocessing and up-scaling of biopharmaceutical production) as well as basic biology.

Director of Research: Professor David Poyner


 Dr Zita Balklava  Dr Stuart  Greenhill   Professor Andy Pitt 
 Professor Roslyn Bill  Dr Stephane Gross  Dr Dan Rathbone
 Dr Alex Cheong  Dr Anna Hine
 Dr Alice Rothnie
 Professor Mike Coleman  Dr Rhein Parri   Professor Corinne  Spickett
 Dr Darren Flower    Professor Gavin Woodhall
 Dr Alan Goddard    Dr Xuming Zhang
Molecular Biomedical Research
Binding of a peptide hormone analogue to the extracellular domain of the calcitonin receptor.


For currently available PhD research projects in the Molecular Biomedical Research Group, see here.

Research Themes:

The Aston Centre for Membrane Protein & Lipid Research (AMPL) is a collaborative team of six principal investigators in biochemistry, pharmacology, protein/lipid chemistry and polymer science.

We study the structure and function of membrane proteins and associated lipids, using interdisciplinary approaches and our novel technologies. Our aim is to understand the molecular basis of how cells communicate with their environment and each other, facilitating drug discovery for patient benefit and driving advances in industrial biotechnology.